U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula C4H5N4O3.Al.2HO
Molecular Weight 218.1037
Optical Activity ( + / - )
Defined Stereocenters 0 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of ALDIOXA

SMILES

[OH-].[OH-].[Al+3].NC(=O)NC1NC(=O)[N-]C1=O

InChI

InChIKey=NZILXMYBYNIXPF-UHFFFAOYSA-K
InChI=1S/C4H6N4O3.Al.2H2O/c5-3(10)6-1-2(9)8-4(11)7-1;;;/h1H,(H5,5,6,7,8,9,10,11);;2*1H2/q;+3;;/p-3

HIDE SMILES / InChI

Molecular Formula Al
Molecular Weight 26.9815
Charge 3
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula HO
Molecular Weight 17.0073
Charge -1
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula C4H6N4O3
Molecular Weight 158.1154
Charge 0
Count
Stereochemistry RACEMIC
Additional Stereochemistry No
Defined Stereocenters 0 / 1
E/Z Centers 0
Optical Activity ( + / - )

Aldioxa is the generic name for the metal complex, dihydroxyaluminum allantoinate, which is hydrolyzed to allantoin and aluminium hydrate at the gastric mucosa. Aldioxa was approved in Japan to improve subjective symptoms or objective of gastric/duodenal ulcer and gastritis. It was discovered, that aldioxa ameliorates delayed gastric emptying through its antagonistic activity on the α-2 adrenergic receptor. The most commonly reported adverse reactions include constipation.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Preventing
BODYGLIDE FOR HER

Approved Use

helps prevent and helps relieve chafed, chapped or cracked skin. helps protect from the drying effects of wind and cold weather. temporarily protects minor cuts, scrapes, burns.

Launch Date

1.25902075E12
Primary
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

protects gastric / duodenal tissue mucosa and helps repair, thus improving gastric / duodenal ulcer and gastritis. It is usually used to improve subjective symptoms or objective of gastric/duodenal ulcer and gastritis.
Primary
Unknown

Approved Use

protects gastric / duodenal tissue mucosa and helps repair, thus improving gastric / duodenal ulcer and gastritis. It is usually used to improve subjective symptoms or objective of gastric/duodenal ulcer and gastritis.
Primary
Unknown

Approved Use

protects gastric / duodenal tissue mucosa and helps repair, thus improving gastric / duodenal ulcer and gastritis. It is usually used to improve subjective symptoms or objective of gastric/duodenal ulcer and gastritis.
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
6.43 μg/mL
10 mg/kg 3 times / day steady-state, oral
dose: 10 mg/kg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
ALLANTOIN plasma
Canis lupus
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
30 μg × h/mL
10 mg/kg 3 times / day steady-state, oral
dose: 10 mg/kg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
ALLANTOIN plasma
Canis lupus
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
2.69 h
10 mg/kg 3 times / day steady-state, oral
dose: 10 mg/kg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
ALLANTOIN plasma
Canis lupus
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
PubMed

PubMed

TitleDatePubMed
[Pharmacological study of dihydroxyaluminum allantoinate and chlorhydroxyaluminum allantoinate. I. Toxicity].
1962 Jul-Aug
[Evaluation of the anti-ulcer drugs using image analysis technology: effect of aldioxa containing preparation on the experimental gastric ulcer in rats].
1989 Nov
[Acidified aspirin-induced gastric lesion in rats with hepatic cirrhosis produced by N-nitrosodiethylamine or carbon tetrachloride. Effect of aldioxa on gastric lesions].
1994 Mar
Aldioxa improves delayed gastric emptying and impaired gastric compliance, pathophysiologic mechanisms of functional dyspepsia.
2015 Dec 1

Sample Use Guides

In Vivo Use Guide
Sources: file:///C:/Users/Mark/Desktop/info_20ALCLOXA.pdf
Antiperspirants, deodorants: Creams, spray, lossions: 0.25-0.5% Baby products: creams; powders: 0.2-0.5%
Route of Administration: Topical
In Vitro Use Guide
Sources: file:///C:/Users/Mark/Desktop/info_20ALCLOXA.pdf
In vitro Alcloxa inhibited formation and bacterial decomposition of pulverized human epidermal scales. The scales were obtained from patient with exfoliative dermatitis, characterized by a great deal of exudation. The scales were were pulverized in a Wiley mill, defatted with ether and suspended in a 0,2% Alcloxa solution.
Substance Class Chemical
Created
by admin
on Fri Dec 15 18:47:51 UTC 2023
Edited
by admin
on Fri Dec 15 18:47:51 UTC 2023
Record UNII
8T66I31YNK
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
ALDIOXA
INCI   INN   MART.   MI   USAN   WHO-DD  
INCI   INN   USAN  
Official Name English
RC 172
Code English
ALDIOXA [MART.]
Common Name English
ALDIOXA [JAN]
Common Name English
ALDIOXA [USAN]
Common Name English
ALDIOXA [MI]
Common Name English
ALUMINUM, DIHYDROXY((4,5-DIHYDRO-2-HYDROXY-5-OXO-1H-IMIDAZOL-4-YL)UREATO)-
Common Name English
ALDIOXA [INCI]
Common Name English
ASCOMP
Brand Name English
aldioxa [INN]
Common Name English
ALUMINIUM DIHYDROXY ALLANTOINATE
Common Name English
ALUMINIUM, DIHYDROXY((4,5-DIHYDRO-2-HYDROXY-5-OXO-1H-IMIDAZOL-4-YL)UREATO)-
Common Name English
ALDA
Code English
RC-172
Code English
ISALON
Brand Name English
ALUMINUM DIHYDROXY ALLANTOINATE
Common Name English
Dihydroxy[2-hydroxy-5-oxo-2-imidazolin-4-yl)ureato]aluminum
Common Name English
Aldioxa [WHO-DD]
Common Name English
DIHYDROXY(2-HYDROXY-5-OXO-2-IMIDAZOLIN-4-YL)UREATO)ALUMINIUM
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C29700
Created by admin on Fri Dec 15 18:47:51 UTC 2023 , Edited by admin on Fri Dec 15 18:47:51 UTC 2023
Code System Code Type Description
DAILYMED
8T66I31YNK
Created by admin on Fri Dec 15 18:47:51 UTC 2023 , Edited by admin on Fri Dec 15 18:47:51 UTC 2023
PRIMARY
EPA CompTox
DTXSID8057774
Created by admin on Fri Dec 15 18:47:51 UTC 2023 , Edited by admin on Fri Dec 15 18:47:51 UTC 2023
PRIMARY
SMS_ID
100000087851
Created by admin on Fri Dec 15 18:47:51 UTC 2023 , Edited by admin on Fri Dec 15 18:47:51 UTC 2023
PRIMARY
ECHA (EC/EINECS)
226-964-4
Created by admin on Fri Dec 15 18:47:51 UTC 2023 , Edited by admin on Fri Dec 15 18:47:51 UTC 2023
PRIMARY
INN
1634
Created by admin on Fri Dec 15 18:47:51 UTC 2023 , Edited by admin on Fri Dec 15 18:47:51 UTC 2023
PRIMARY
FDA UNII
8T66I31YNK
Created by admin on Fri Dec 15 18:47:51 UTC 2023 , Edited by admin on Fri Dec 15 18:47:51 UTC 2023
PRIMARY
EVMPD
SUB05305MIG
Created by admin on Fri Dec 15 18:47:51 UTC 2023 , Edited by admin on Fri Dec 15 18:47:51 UTC 2023
PRIMARY
NCI_THESAURUS
C76519
Created by admin on Fri Dec 15 18:47:51 UTC 2023 , Edited by admin on Fri Dec 15 18:47:51 UTC 2023
PRIMARY
RXCUI
23161
Created by admin on Fri Dec 15 18:47:51 UTC 2023 , Edited by admin on Fri Dec 15 18:47:51 UTC 2023
PRIMARY RxNorm
CAS
5579-81-7
Created by admin on Fri Dec 15 18:47:51 UTC 2023 , Edited by admin on Fri Dec 15 18:47:51 UTC 2023
PRIMARY
MESH
C017231
Created by admin on Fri Dec 15 18:47:51 UTC 2023 , Edited by admin on Fri Dec 15 18:47:51 UTC 2023
PRIMARY
MERCK INDEX
m1486
Created by admin on Fri Dec 15 18:47:51 UTC 2023 , Edited by admin on Fri Dec 15 18:47:51 UTC 2023
PRIMARY Merck Index
Related Record Type Details
ACTIVE MOIETY